UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MM-559 Update on Predictors of Progression in Smoldering Multiple Myeloma: A Systematic Review

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S571-S572

2024

Volltextzugriff (PDF)

3D osteocyte lacunar morphometry of human bone biopsies with high resolution microCT: From monoclonal gammopathy to newly diagnosed multiple myeloma

Bone (New York, N.Y.), 2024-08, p.117236, Article 117236

2024

Volltextzugriff (PDF)

Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance

Blood cancer journal (New York), 2024-08, Vol.14 (1), p.148-7

2024

Volltextzugriff (PDF)

MM-746 Dose-Adjusted Melphalan Yields Comparable MRD-Negativity to Full-Dose Melphalan in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S582-S583

2024

Volltextzugriff (PDF)

MM-681 Immunoparesis in Newly Diagnosed Multiple Myeloma and Its Impact on Clinical Outcome: A Real-World Experience

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S579-S579

2024

Volltextzugriff (PDF)

MM-563 Immunotherapy Revealing Promising Outcomes in Smoldering Myeloma: A Systematic Review

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S572-S572

2024

Volltextzugriff (PDF)

MM-739 Infectious Complications After Hematopoietic Cell Transplantation in Multiple Myeloma Patients: Characteristics and Outcomes

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S581-S582

2024

Volltextzugriff (PDF)

MM-689 Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplant in Multiple Myeloma Patients: Assessing Real-World Impact on Treatment Outcomes and Beyond

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S579-S579

2024

Volltextzugriff (PDF)

MM-599 The Outcome of Management of Multiple Myeloma in Sudanese Patients

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S575-S575

2024

Volltextzugriff (PDF)

MM-268 Role of Tp53 Alterations in Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S542-S542

2024

Volltextzugriff (PDF)

CART Should be Reserved for Late Relapse > 3 Lines

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S95-S95

Usmani, Saad Z

2024

Volltextzugriff (PDF)

MM-731 Prognostic Implications of Immune Paralysis in Newly Diagnosed Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S581-S581

2024

Volltextzugriff (PDF)

MM-294 Exploring the Link Between High-Risk Cytogenetics and Skeletal Lytic Lesions in African American (AA) Multiple Myeloma (MM) Patients: Insights From a Decade-Long Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S544-S544

2024

Volltextzugriff (PDF)

MM-722 Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide Thalidomide, Dexamethasone, and Daratumumab

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S580-S580

2024

Volltextzugriff (PDF)

MM-571 Efficacy and Safety Analysis of Daratumumab-Integrated Quadruple Therapy vs Triple Therapy for Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma: A Systematic Review and Meta-Analysis

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S573-S573

2024

Volltextzugriff (PDF)

MM-505 Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S564-S565

2024

Volltextzugriff (PDF)

Quadruplet Therapy May Be the New Frontline SOC in Multiple Myeloma

Oncology (Williston Park, N.Y.), 2024-08, Vol.38 (8 8)

ONCOLOGY Staff

2024

Volltextzugriff (PDF)

Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma

Journal of molecular biology, 2024-10, Vol.436 (20), p.168748, Article 168748

2024

Volltextzugriff (PDF)

PDCD4 interacting with PIK3CB and CTSZ promotes the apoptosis of multiple myeloma cells

The FASEB journal, 2024-08, Vol.38 (16), p.e70024-n/a

2024

Volltextzugriff (PDF)

Recent advancements in nanomedicine as a revolutionary approach to treating multiple myeloma

Life sciences (1973), 2024-11, Vol.356, p.122989, Article 122989

2024

Volltextzugriff (PDF)

MM-494 Beyond the Surface: A Case Study of Cutaneous Involvement in Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S563-S563

2024

Volltextzugriff (PDF)

MM-188 Unveiling the Spectrum of FISH Abnormalities in a Decade-Long Retrospective Study of Multiple Myeloma Patients: Insights From an Underrepresented Population

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S539-S540

2024

Volltextzugriff (PDF)

MM-543 Prognostic Value of Inflammatory Factors in Extramedullary Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S568-S569

2024

Volltextzugriff (PDF)

MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S561-S562

2024

Volltextzugriff (PDF)

MM-121 Extramedullary Multiple Myeloma - Report of a Case Manifested as a Retroperitoneal Mass and Cholestatic Syndrome

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S537-S537

2024

Volltextzugriff (PDF)

1 – 25 von 172

Suche als RSS-Feed

Aktive Filter

Neu hinzugefügt... seit 30 Tagen

ThemaBone Marrow

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(158)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Multiple Myeloma
(155)
Science & Technology
(17)
Oncology
(16)
Life Sciences & Biomedicine
(14)
Patients
(11)
Antigens
(8)
Cancer Therapies
(8)
Daratumumab
(8)
Hematology
(8)
Leukemia
(8)
Medicine
(8)
Immunology
(7)
Proteins
(7)
Relapsed/refractory Multiple Myeloma
(7)
Anemia
(6)
Bispecific Antibody
(6)
Bortezomib
(6)
Chemotherapy
(6)
Phase 3
(6)
Case Reports
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

MM-559 Update on Predictors of Progression in Smoldering Multiple Myeloma: A Systematic Review

3D osteocyte lacunar morphometry of human bone biopsies with high resolution microCT: From monoclonal gammopathy to newly diagnosed multiple myeloma

Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance

MM-746 Dose-Adjusted Melphalan Yields Comparable MRD-Negativity to Full-Dose Melphalan in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

MM-681 Immunoparesis in Newly Diagnosed Multiple Myeloma and Its Impact on Clinical Outcome: A Real-World Experience

MM-563 Immunotherapy Revealing Promising Outcomes in Smoldering Myeloma: A Systematic Review

MM-739 Infectious Complications After Hematopoietic Cell Transplantation in Multiple Myeloma Patients: Characteristics and Outcomes

MM-689 Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplant in Multiple Myeloma Patients: Assessing Real-World Impact on Treatment Outcomes and Beyond

MM-599 The Outcome of Management of Multiple Myeloma in Sudanese Patients

MM-268 Role of Tp53 Alterations in Multiple Myeloma

CART Should be Reserved for Late Relapse > 3 Lines

MM-731 Prognostic Implications of Immune Paralysis in Newly Diagnosed Multiple Myeloma

MM-294 Exploring the Link Between High-Risk Cytogenetics and Skeletal Lytic Lesions in African American (AA) Multiple Myeloma (MM) Patients: Insights From a Decade-Long Study

MM-722 Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide Thalidomide, Dexamethasone, and Daratumumab

MM-571 Efficacy and Safety Analysis of Daratumumab-Integrated Quadruple Therapy vs Triple Therapy for Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma: A Systematic Review and Meta-Analysis

MM-505 Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D

Quadruplet Therapy May Be the New Frontline SOC in Multiple Myeloma

Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma

PDCD4 interacting with PIK3CB and CTSZ promotes the apoptosis of multiple myeloma cells

Recent advancements in nanomedicine as a revolutionary approach to treating multiple myeloma

MM-494 Beyond the Surface: A Case Study of Cutaneous Involvement in Multiple Myeloma

MM-188 Unveiling the Spectrum of FISH Abnormalities in a Decade-Long Retrospective Study of Multiple Myeloma Patients: Insights From an Underrepresented Population

MM-543 Prognostic Value of Inflammatory Factors in Extramedullary Multiple Myeloma

MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

MM-121 Extramedullary Multiple Myeloma - Report of a Case Manifested as a Retroperitoneal Mass and Cholestatic Syndrome

Aktive Filter

Suchergebnisse filtern